- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
Beginning June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers to treat asthma and chronic obstructive pulmonary disease (COPD). Included are:
- Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
- Combivent Respimat® (ipratropium bromide and albuterol) Inhalation Spray
- Spiriva HandiHaler(tiotropium bromide inhalation powder)
- Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray
- Spiriva® Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray
- Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray
- Striverdi Respimat (olodaterol) Inhalation Spray
The company said in a press release that it will decrease the list price on some of its inhaler products and will continue providing rebates off the list price of its medicines to insurers and pharmacy benefits managers.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
